Introduction
The crucial role of tyrosine phosphorylation in control of cell growth, motility, and invasiveness is re¯ected in the contribution of tyrosine kinases to neoplastic transformation (Porter and Vaillancourt, 1998) . In breast cancer, HER2/neu overexpression is an important prognostic indicator, and constitutes a therapeutic target (Ross and Fletcher, 1999) , but other receptor tyrosine kinases (RTKs) are also overexpressed (Barker et al., 1995; Ellis et al., 1998; Ghoussoub et al., 1998; Maggiora et al., 1998) .
Increased activity of (non-receptor) Src-family kinases (SFKs) in neoplasia has been recognized for a long time (Maa et al., 1995; Muthuswamy et al., 1994; Ottenho-Kal et al., 1992) . Firm genetic evidence implicating c-Src in human cancer was provided recently by the ®nding of a Src-activating point mutation in advanced colon tumors (Irby et al., 1999) . This somatic mutation introduces a stop codon immediately adjacent to Y530, which constitutes the main negative regulatory phosphorylation site of SFKs. Phosphorylated Y530 stabilizes an inactive conformation through intramolecular interaction with the c-Src SH2 domain (Schwartzberg, 1998) . The mutation enhances c-Src kinase activity, and is transforming, tumorigenic, and promotes metastasis (Irby et al., 1999) , providing powerful evidence that selection for SFK activation contributes to tumor progression.
The biological activity of tyrosine kinases is highly context-dependent, and the identi®cation of cellular modi®ers of tyrosine-kinase initiated responses has therefore constituted a rewarding ®eld of study. For instance, the signaling pathways downstream of HER2/ neu are co-determined by its heterodimerization partners within the erbB family (Carraway and Cantley, 1994) . Two membrane proteins were recently shown to modulate HER2/neu or EGF-receptor signaling (Carraway et al., 1999; Kharitonenkov et al., 1997) .
The activity of SFKs is controlled by RTKs, the non-receptor kinase Csk, and protein tyrosine phosphatases (PTPs) (Schwartzberg, 1998) . While altered expression or activity of PTPs might contribute to neoplasia, their role in, or behavior during, tumor progression is almost completely unstudied. The concept of clinically relevant, anti-oncogenically acting, PTPs has received support in the case of PTEN/ MMAC, but the lipid phosphatase activity of the latter may be the actual mediator of its biological function (Maehama and Dixon, 1999) . However, PTPs can also act as positive regulators. They may increase substrate phosphorylation/dephosphorylation cycling rates (Fischer et al., 1991) . SHP-2 is required for the response to some mitogens (Feng, 1999) . CD45, by acting as an activator of SFKs, is required for tyrosine phosphorylation and other signaling events upon T-cell receptor activation (Neel, 1997) . However, inhibitory roles for SHP-2 and CD45 have also been described; the function of PTPs in growth control may thus be lineage-and signal-speci®c (Petrone and Sap, 2000) .
PTPs constitute a large family of structurally diverse enzymes (Neel and Tonks, 1997) . Only very few studies so far have addressed the possibility of deregulation of members of this family in breast cancer. Certain PTPs can inhibit growth of breast cancer cell lines (Keane et al., 1996; Zhai et al., 1995) . PTP activity rises when breast cancer cells are growth inhibited by antiestro-gens (Freiss and Vignon, 1994) . In primary human tumors, membrane PTP activity correlates with the presence of tumor positive axillary lymph nodes, whereas cytosolic activity correlates with the mitotic index (Ottenho-Kal et al., 1995) . Increased PTPe levels were observed in mouse tumors induced by HER2/neu or v-Ha-Ras, but not by c-myc or int-2 (Elson and Leder, 1995b) , and constitutive PTPe expression increases the risk of mammary tumor development in transgenic mice (Elson, 1999) .
In this study, we focused our attention on RPTPa. Three features of this receptor PTP suggest its potential relevance to oncogenic transformation. First, it is associated, via a tyrosine phosphorylation site in its C-terminus, with the Grb2 adaptor (den Hertog and Hunter, 1996; Su et al., 1996) , a regulator of Ras. We and others have shown that simultaneous association of Grb2 with the Ras activator Sos and with RPTPa is probably mutually exclusive, making it unlikely that RPTPa activates Ras by membrane recruitment of Sos (den Hertog et al., 1994; Su et al., 1996) . However, Sos recruitment by Grb2 to RPTPa is not the only way in which RPTPa may aect Ras signaling; for instance, RPTPa may sequester Grb2 away from Sos; or Grb2 may recruit Grb2-bound docking proteins for dephosphorylation by RPTPa. Second, overexpression of RPTPa is observed in advanced human colon carcinoma (Tabiti et al., 1995) , and a closely related PTP, RPTPe, is implicated in mouse mammary tumorigenesis (Elson and Leder, 1995b) (Elson, 1999) . Third, RPTPa is an important regulator of SFK activity, by controlling dephosphorylation of the carboxy-terminal negative regulatory Y530 site of cSrc. Cells lacking RPTPa display reduced Fyn and cSrc kinase activities, and exhibit defects similar to those resulting from lack of c-Src (Ponniah et al., 1999; Su et al., 1999) . Conversely, RPTPa overexpression results in elevated c-Src kinase activity (den Hertog et al., 1993; Zheng et al., 1992 Zheng et al., , 2000 . Intriguingly, activation of the c-Src kinase is often observed in breast and colon tumors (Cartwright et al., 1990; Ottenho-Kal et al., 1992) , and can potentiate signaling by the ErbB family (Tice et al., 1999) .
The properties of RPTPa thus led us to hypothesize that it could promote neoplastic transformation or progression. We were particularly guided by the hypothesis that increased RPTPa expression might occur in tumors as a result of selective pressure for enhanced c-Src kinase activity, and would correlate with more advanced disease. To test this issue, we analysed RPTPa expression in primary breast tumors, and the eect of its transfection on growth of breast carcinoma cell lines. Unexpectedly, we observed that overexpression of RPTPa is associated with lower grade, and while activating c-Src, acts in an antiproliferative manner in vitro and in vivo.
Results

High levels of RPTPa protein in a subset of human breast tumors
Cases of primary breast carcinoma were analysed for RPTPa expression by anti-RPTPa immunoblotting of protein lysates extracted from samples obtained at surgery. This analysis revealed, in a subset of tumors, a single 130 kDa protein species reacting with an antiRPTPa antiserum raised against the intracellular domain of the protein (Figure 1 ). In transient transfection experiments in 293 cells, this antibody had shown marginal cross-reactivity with RPTPe, the PTP most closely related to RPTPa (data not shown). To con®rm speci®city, and to exclude cross-reaction with RPTPe, samples were therefore also analysed by immunoprecipitation using antiserum 210, directed against an epitope which is not conserved between RPTPa and RPTPe, followed by immunoblotting with antiserum 35, against the C-terminus of RPTPa. This experiment (not shown) con®rmed that the protein species seen in Figure 1 corresponded to RPTPa. Analysis of a total of 51 cases revealed that, whereas RPTPa was only marginally detectable in the majority of tumors, its expression was substantially increased in 15 tumor samples out of the 51 analysed (29%). In the case of 13 patients, we were able to simultaneously analyse non-diseased tissue neighboring the tumor. While ®ve out of the 13 corresponding tumors (38%) manifested increased RPTPa protein expression levels, all of the 13 matched normal neighboring tissue samples displayed a barely detectable background level of RPTPa expression (Figure 1 and data not shown).
RPTPa expression correlates with low tumor grade
We subsequently analysed the correlation between RPTPa overexpression and pathological, clinical and biological parameters. No dierences in histotype distribution were observed between non-expressing (5/ 36=14% lobular; 29/36=80% ductal) and RPTPa expressing (2/15=13% lobular; 11/15=73% ductal) carcinomas.
However, as shown in Table 1 , high level expression of RPTPa was found signi®cantly correlated with low grade (P=0.02) (Pereira et al., 1995) , and positive estrogen receptor status (P=0.04). In addition, RPTPa-positive tumors tended to be HER2/neunegative, to display lower proliferation indices, to be of smaller size, and to manifest a lower degree of lymph node involvement, although these distinctions were not at the level of statistical signi®cance.
High RPTPa expression in human tumors is not due to gene amplification
To investigate if overexpression of RPTPa was due to gene ampli®cation, we performed Southern blot analysis on genomic DNA extracted from the primary tumors. Eleven cases that resulted positive for RPTPa overexpression (as revealed by immunoblotting), one case with no overexpression, and one normal mammary tissue sample were analysed using two dierent probes corresponding to the extracellular region of RPTPa, as well as using a b-actin probe (to normalize for loading). The results, shown in Figure 2a , indicate that none of the cases under study displayed RPTPa gene ampli®cation.
Elevated RPTPa protein levels in human tumors correlate with enhanced mRNA levels
In the absence of ampli®cation as a plausible mechanism (Figure 2a ), we performed Northern analysis on a subset of the tumors analysed, to determine whether dierences in RPTPa protein expression might re¯ect dierences in mRNA content. In this experiment, we observed that three out of three tumors known to express high RPTPa protein levels (18667, 06891 and 18561; i.e. three right lanes) contained signi®cantly higher level RPTPa mRNA levels than four cases that had tested undetectable for RPTPa protein (14415, 02349, 08874 and 06968; i.e. four left lanes) ( Figure 2b ). This result indicates that increased mRNA levels are the likely mechanism behind the enhanced RPTPa protein levels seen in primary tumors. Of note, enhanced RPTPa mRNA levels were also observed in a subset of primary human colon cancer cases (Tabiti et al., 1995) .
RPTPa overexpression in mammary cells leads to decreased growth capability
The eect of RPTPa on growth parameters was investigated in the human breast cancer cell line MCF7. In a ®rst approach, an RPTPa expression vector (or the corresponding empty vector control) was transfected into MCF7 cells, and the number of The level of statistical signi®cance was determined using Fisher's test. Not all parameters were available for all tumors, hence the instances were sometimes less than the total of 51 cases. N+: presence of pathological nodal metastasis (number of metastasis-containing lymph nodes). ER: Estrogen receptor. PgR: progesterone receptor (Figure 3a) . Three dierent RPTPa overexpressing clones were randomly chosen for Figure 3 RPTPa expression inhibits in vitro growth rate due to extension of G1 phase of the cycle. (a) Immunoblotting analysis of RPTPa expression in stably transfected MCF7 clones. Total protein lysates from an empty vector transfected clone (Neo) and from three RPTPa cDNA transfected clones (a-4, a-6, and a-9) were immune precipitated with anti-RPTPa antiserum and blotted with the same antiserum. The smaller form of the protein corresponds to a dierentially glycosylated precursor, which tends to become enriched in immune precipitations (Daum et al., 1994) . (b) Activation of c-Src kinase activity as a result of RPTPa expression. Top: in vitro kinase assay; c-Src was immune precipitated from an empty vector transfected cell clone (Neo) and 3 RPTPa-expressing clones (a-4, a-6, a-9) and subjected to in vitro kinase reaction in the presence of g-32 P-labeled ATP, using enolase as exogenous substrate. Bottom: Anti-Src immunoblot; an aliquot of the c-Src immune precipitate was subjected to anti-Src immunoblotting. (c) Eect of RPTPa expression on growth rate. Parental MCF7 cells (&), a vector (control) transfected MCF7 cell clone (*), and three RPTPa-expressing clones (^: a-4;~: a-6, !: a-9) were seeded at equal initial densities, and growth measured using the Sulphorodamine B dye uptake method (Pizao et al., 1992) . The t=0 timepoint corresponds to 18 h after plating. A representative of three independent experiments is shown. Error bars indicate standard deviation (n=6 wells/time-point/clone). (d) Cell cycle distribution in an empty vector transfected clone (neo) and two RPTPa expressing lines (a-4 and a-9). Exponentially growing cells were trypsinized, ®xed, and stained with propidium iodide, and¯uorescence measured by¯ow cytometry subsequent studies. Consistent with reports for other cell lines (den Hertog et al., 1993; Zheng et al., 1992) , increased RPTPa expression led to elevated c-Src kinase activity (as measured by in vitro kinase assay vis-a-vis enolase as an exogenous substrate) ( Figure  3b) ; this is presumably due to dephosphorylation by RPTPa of the negative regulatory site Y530 in c-Src.
Analysis of in vitro growth properties also revealed that the growth rate of RPTPa-expressing clones was signi®cantly decreased in comparison with that of parental or empty vector-transfected cells (Figure 3c ). The decrease of growth in the transfected clones, evident in the ®rst days after plating, was not due to dierent plating eciency as evaluated by number of adherent cells 18 h after plating (time-point 0 in Figure  3c ). This observation was investigated further through cell cycle analysis by¯ow cytometry at 24 h from plating. Figure 3d shows a representative experiment, in which the results obtained for one control and two RPTPa-overexpressing clones (a-4 and a-9) are indicated. In three independent experiments, the proportion of cells in G 0 /G 1 was in the range of 35 ± 40% for parental or empty transfected cells; by contrast, for RPTPa-overexpressing clones, the fraction of cells in G 0 /G 1 was increased to 62 ± 78%. The proportion of cells in S phase was also reduced by RPTPa: for parental and empty transfected cells, values in the range of 40 ± 44% were found, whereas in RPTPaoverexpressing clones the number in S phase was decreased to 29% (clone a-4) and down to 13% in the highest expressing clone (a-9). The absence of any sub-G 1 (hypodiploid) peak after propidium staining in our cell cycle analysis suggests that the growth inhibition is not accompanied by apoptotic cell death in RPTPaoverexpressing clones.
RPTPa expression reduces tumor growth and delays metastasis
The human MCF7 line is only poorly tumorigenic when inoculated into immuno-de®cient test animals. Therefore, to analyse the consequences of RPTPa overexpression for tumor growth in vivo, we expressed RPTPa in N202.1A cells, a mouse line derived from a mammary tumor induced by transgenic expression of the HER2/neu protooncogene in the mammary epithelium (Lollini et al., 1998) . N202.1A cells were infected in vitro with a retrovirus encoding RPTPa, or (as the control) virus corresponding to the empty retroviral vector. Cells growing out after infection with either virus and the corresponding selection were pooled, so as to neutralize any eects of random clonal variability, and immunoblotting analysis con®rmed the presence of RPTPa in cells infected with RPTPa encoding retrovirus (Figure 4a ). Similar to the case for MCF-7 cells (Figure 3c,d ), RPTPa expression in N202.1A cells resulted in signi®cant inhibition of the in vitro proliferation rate (data not shown). Control or RPTPa-expressing N202.1A cell pools were then inoculated into 6-week-old Balb/c athymic mice, with the aim to monitor the eect of RPTPa expression on tumor growth (following subcutaneous injection), or on metastatic ability (following intravenous injection). As shown in Figure 4b tumor growth in animals injected subcutaneously with RPTPa-expressing cells was signi®cantly reduced as compared to animals injected with the control cell population. In a separate experiment, control or RPTPa-expressing cells were injected intravenously, and lung metastasis monitored by necropsy after animals developed dyspnea. All (15/15) mice injected with control cells developed lung 6 cells/each and examined daily for dyspnea, at which point the animal was sacri®ced and lung metastasis con®rmed by autopsy. The experiment was terminated at day 50. A representative of two independent experiments is shown; Chi-square analysis for this experiment indicated a Pvalue50.001 for the dierence between the two survival curves Oncogene Tyrosine phosphatase RPTPa in human breast tumors E Ardini et al metastases within 39 days (median=34); by contrast, the median delay until a similar metastasis burden for RPTPa-expressing cells was 43 days, with 3/15 animals still remaining symptom-free after 50 days (Figure 4c ). Chi-square analysis revealed that this median delay of 9 days until metastatic symptoms was statistically signi®cant at the P50.0001 level.
Discussion
Our observations show that a subclass (approximately one-third) of primary breast carcinomas is characterized by strongly elevated levels of RPTPa, and that this phenomenon is associated with lower tumor grade. To our knowledge, this is the ®rst example of a study correlating expression level of a bona ®de PTP with neoplastic disease status in humans. Furthermore, our experiments on breast cancer cells transfected with RPTPa show that enhanced RPTPa expression led to reduced growth rates in vivo and in vitro, an experimental eect not inconsistent with our clinical observation.
That enhanced RPTPa expression correlates with reduced tumor aggressiveness, and inhibits the growth rate and tumorigenicity of transfected cells was somewhat unexpected. The ability of RPTPa to activate the c-Src kinase (den Hertog et al., 1993; Su et al., 1999) , sometimes with transforming eects (Zheng et al., 1992 (Zheng et al., , 2000 , rather suggested a role for RPTPa as a potential oncogene itself, or as an enhancer of tumorigenicity. The recent ®nding of a Src-activating mutation in advanced human colon tumors (Irby et al., 1999) indeed points at the existence of selective pressure towards c-Src activation in advanced tumors. Increased RPTPa mRNA expression was also noted in 10 out of 14 advanced (Dukes' stage D) colon adenocarcinoma samples (Tabiti et al., 1995) ; however, this study did not include a comparison between more and less advanced tumors, and thus did not address the issue discussed here. A survey of various transgenic mouse models for mammary tumor development showed consistent overexpression of RPTPe, a PTP highly related to RPTPa, in HER2/Neu-or v-Ha-Rasinduced tumors (Elson and Leder, 1995b) . These observations led to suggestions that increased PTP expression could constitute a tumor progression step, for instance by driving enhanced c-Src activity. However to what extent RPTPa, among the many potential regulators of c-Src, contributes to src activation in human tumor settings remains unestablished. In a pilot analysis of c-Src kinase activity in a subset of tumors analysed, we failed to observe a simple 1 : 1 correlation between RPTPa overexpression and c-Src activation (data not shown). A recent biochemical approach concluded that RPTPa is not the major Src-activating PTP in breast cancer cell lines (Egan et al., 1999) .
Several considerations may reconcile the apparent con¯ict between the Src-activating and ®broblast transforming capacity of RPTPa, and our present observations that RPTPa expression correlates with lower grade and reduces experimental tumor cell growth. First, RPTPa-induced Src activation may exert dierent eects in dierent settings or cellular contexts. Analogously, HER2/neu is tumorigenic in 3T3 ®bro-blasts (Di Fiore et al., 1987) , yet when overexpressed in MCF7 breast carcinoma cells leads to growth inhibition and dierentiation (Giani et al., 1998) . One mechanism through which Src family kinases have been linked to negative growth regulation is phosphorylation of the Cbl protein, leading to degradation of PDGFR-a (Rosenkranz et al., 2000) . Second, whereas good evidence indicates that RPTPa activates c-Src, other thus far unidenti®ed targets for RPTPa likely exist, whose dephosphorylation leads to growth arrest. Indirect evidence implicates RPTPa in inhibition of insulin signaling, through unknown mechanisms. Third, all human tumors analysed here had reached the stage of clinically recognizable disease. Therefore, it is possible that high RPTPa expression in a subset of tumors is a remnant of an earlier disease stage, where it may have contributed to initiation, or early progression, but is lost at later stages in favor of more aggressive progression events. Interestingly, transgenic expression of PTPe enhances the incidence of mammary malignancy, but the ensuing tumors express very low PTPe levels (Elson, 1999) , consistent with a speci®c role of this PTP in early stages of progression only. Ultimately, transgenic models may be useful to further dissect the potential contribution of RPTPa to tumor initiation and/or progression.
The above considerations try to reconcile the transforming and c-Src activating potential of RPTPa with our observation that RPTPa expression preferentially occurs in low-grade tumors and inhibits tumor cell growth. Yet, more indirect connections are equally plausible. For instance, tumors that express RPTPa may belong to a biologically distinct subclass, for which RPTPa expression merely constitutes a marker. However, given the striking and unexpected negative eects of RPTPa expression on the growth of experimental tumors and on cell cycle distribution, it is tempting to propose that high RPTPa expression is the result of a feedback response to an alteration in cellular homeostasis. Under normal conditions, tyrosine phosphorylation is tightly regulated by the equilibrium between cellular PTKs and PTPs. A perturbation of this balance, for instance as a result of a speci®c oncogene activation, may lead to feedback responses including the increased expression of particular PTPs. Dual-speci®city phosphatases that inactivate ERK kinases are induced as a consequence of the same stimuli that lead to ERK activation (Brondello et al., 1997; Sun et al., 1993) . Increased expression of the PTPs LAR and PTP1B was observed in human breast epithelial cell lines as a consequence of HER2/neu expression (Zhai et al., 1993) , and LAR was shown to suppress transformation by this oncogene (Zhai et al., 1995) . RPTPs are also induced in many cases as a response to increased cell density, raising the possibility that this induction participates in contact inhibition (Ostman et al., 1994) . Hence, increased RPTPa expression could constitute a feedback response to an as yet unidenti®ed tumorigenic insult, or stimulus. One tyrosine phosphorylation-mediated pathway activated in human breast tumors involves the HER2/neu oncogene (Tzahar and Yarden, 1998) . Experimental murine HER2/neu-induced mammary tumors express high levels of the RPTPa-like PTPe (Elson and Leder, 1995b) , and our study detected a weak and inverse correlation between RPTPa expression in human tumors and HER2/neu positivity (Table 1) . At any rate, we believe that the data presented in this paper warrant an exploration of the concept that PTPs in tumors act as non-constitutive, inducible tumor suppressors, whose expression is then lost again at further stages of progression.
The growth inhibition seen as a result of RPTPa expression is related to cell cycle arrest in G 1 . This suggests that a phosphoprotein involved in cell cycle control could be a speci®c substrate for RPTPa. v-Src is capable of inducing cyclin D1 in MCF7 cells (Lee et al., 1999) . It is unclear to what extent c-Src activation by RPTPa is comparable to v-Src expression, and the arrest-inducing eect of RPTPa may or may not be mediated through Src family kinases. A further molecular analysis of the cell cycle blocking eect of RPTPa will require more insight into the signaling pathways downstream of this widely expressed PTP. The membrane localization of RPTPa does not exclude the possibility that it could act on substrates localized in other compartments. RPTPe, related to RPTPa, exists in both cytoplasmic and trans-membrane forms (Elson and Leder, 1995a) . Furthermore, cleavage of the ectodomain of membrane PTPs can induce cellular redistribution of the catalytic domain (Aicher et al., 1997) .
An intriguing possible clue to the mechanism behind the ability of RPTPa to block cell cycle progression in vitro and experimental tumor growth rate in vivo is provided by the ability of RPTPa to block insulin responsiveness; this eect has now been observed in several cell types using various insulin response parameters: anti-adhesive eects in BHK cells (Moller et al., 1995) , prolactin promoter activation in GH4 pituitary cells (Jacob et al., 1998) , and GLUT4 translocation in adipocytes (Cong et al., 1999) . However, the target of RPTPa in insulin signaling is as yet unknown. Insulin-like growth factors are clearly implicated in progression through the cell cycle, proliferation, and inhibition of apoptosis of breast cancer cells in vitro (Ellis et al., 1998; Werner and Le Roith, 1997) . Moreover, ®broblasts lacking the IGF-1 receptor are resistant to transformation by dominant acting oncogenes (Sell et al., 1994) . The ensuing hypothesis, that the inverse correlation between RPTPa expression and mammary tumor progression re¯ects the potential of RPTPa to counteract the eects of insulin-like growth factors, is readily testable.
Materials and methods
Human tumor samples
Fifty-one samples of pathologically con®rmed primary breast carcinoma, or neighboring non-diseased tissue from the same patient, were used. All patients were enrolled at the National Cancer Institute of Milan, and underwent surgery with complete axillary dissection. Mean tumor size at pathological examination was 33.7 mm (range 15 ± 80). According to TNM classi®cation (UICC, 1997), ten patients were classi®ed for tumor size as pT1 (42 cm) (20%), 34 as pT2 (2 ± 5 cm) (68%), and six as pT3 (45 cm) (12%). Twelve patients (23.5%) had no axillary lymph node involvement at histologic examination; among those with pathologic nodal metastasis, 17 (43.6%) had limited axillary metastatic involvement (1 ± 4 metastatic nodes), whereas 22 (56.4%) had a high number of metastatic nodes. All patients had in®ltrating carcinoma: 40 (78%) had in®ltrating ductal carcinoma, seven patients (14%) in®ltrating lobular carcinoma, and the remaining four (8%) a less frequent histotype.
Tissues (tumor, or neighboring non-diseased tissue from the same patient) were collected within 5 min of surgical resection, snap frozen in liquid N 2 and stored at 7808C until use. Primary tumor diameter and axillary nodal status were obtained from histopathological reports. Hematoxylin/eosinstained histologic slides were reviewed for diagnostic reassessment of histotype, grading, necrosis, and proliferation index. Histologic grading was performed according to Elston, considering tubule formation, nuclear morphology and number of mitoses (Elston, 1984; Pereira et al., 1995) . The latter was scored as`+' in case of 41, or`7' for 41, mitosis per ®eld after analysis of at least 10 microscopic ®elds at 4006magni®cation. Proliferation index was evaluated by [ 3 H]-thymidine incorporation, with 2.3% of labeled cells being the cut-o value (Silvestrini et al., 1985) . Estrogen and progesterone receptor analysis relied on antibodies ER1D5 and 1A6 (both DBA, Italy), and scored according to (McCarty et al., 1985) . HER2/neu staining used antibody CB11 (YLEM, Italy), and scored positive when showing strong membrane labeling in 420% of tumor cells (cytoplasmic reactivity was not considered).
Immunoblotting analysis
Specimens were homogenized and lysed for 1 h on ice in RIPA (50 mM Tris pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% Na deoxycholate, 0.1% SDS, 1 mM Na 3 VO 4 , 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin). Lysates were clari®ed for 15 min at 15 000 g. Protein concentration was evaluated using the Bradford assay, and 100 mg protein extract loaded for Western analysis. For immunoprecipitation, ProteinA-Sepharose was incubated with antibody for 1 h at 48C, washed three times with RIPA, and then incubated with 1 mg of lysate for 2 h at 48C. Immune complexes were washed three times with RIPA and eluted at 958C in Laemmli buer. Proteins were separated by 10% SDS ± PAGE and transferred to a nitrocellulose membrane (Hybond C, Amersham). Immunoblotting followed standard procedure, with visualization using an ECL system (Amersham). Anti-RPTPa antibodies used were: 443, against the intracellular domain; 35, against the C-terminus (residues 785 ± 802); and 210, against residues 518 ± 531 (numbering according to Kaplan et al. (1990) .
Southern analysis
Genomic DNA was extracted using the SDS-Proteinase K method, digested with EcoRI, run on 0.8% agarose gel, and transferred to nitrocellulose. The probe (nucleotides 778 ± 1107; Kaplan et al., 1990) was prepared by EcoNI digestion of the human RPTPa cDNA, and labeled with a-[ 32 P]dCTP by random priming (Boehringer). Normalization for loading was achieved by re-hybridization with a b-actin probe and densitometric scanning to determine RPTPa/b-actin signal ratios.
Northern analysis
Total RNA was extracted (RNAzol B kit; Biotecx Laboratories), and 20 mg/sample electrophoresed on a 1% agarose formaldehyde gel, transferred to nitrocellulose and immobilized by UV-cross-linking. Hybridization was performed in FBI-buer (7% SDS, 1.5% SSPE, 10% PEG-8000) using as probe the entire human radiolabeled RPTPa cDNA. The membrane was washed with 0.16SSC+0.1% SDS for 20 min at 258C followed by 20 min at 428C. After stripping, the membrane was re-hybridized with a b-actin probe, and RPTPa/b-actin ratios determined by densitometric scanning.
Cells and transfections
Human breast carcinoma MCF7 and human kidney 293T cells were obtained from ATCC (Rockville, MD, USA). The mouse mammary carcinoma cell line N202.1A (derived from HER2/neu protooncogene transgenic mice) was provided by Dr PL Lollini (Lollini et al., 1998) . All cells were maintained in DMEM+10% FCS. Full length mouse RPTPa cDNA was excised with XhoI and ThaI, and subcloned between the XhoI and EcoRV sites of pcDNA3/neo (Invitrogen). MCF7 cells were transfected with pcDNA3/RPTPa(wt) or with pcDNA3/ neo (control) using calcium phosphate, and single colonies expanded in G418 (500 mg/ml). For colony assays, MCF7 cells (5610 5 cells/ 100 mm plate, seeded 24 h before transfection) were transfected in duplicate by lipofectinmediated gene transfer (Life Technologies). After 3 weeks of selection in G-418, plates were stained using Diquick (Baxter). N202.1A cells were infected with pLXSHD-derived, RPTPa-expressing or control retroviruses (Su et al., 1996) and selected in 4 mM histidinol.
Proliferation assay
Equal numbers of cells were seeded in 96-well plates, and the ®rst time-point (t=0) taken 18 h after seeding. Wells were ®xed for 1 h at 48C in ice cold 10% TCA. Cells were then washed with PBS, and incubated for 30 min with 0.4% Sulphorodamine B in 1% acetic acid (100 ml/well). After three washes in 1% acetic acid, the dye was dissolved in 10 mM Tris pH 10.5 (100 ml/well) and spectrophotometrically evaluated at 492 nm (Pizao et al., 1992) .
Src kinase assay
Lysates were subjected to immune precipitation with anti-Src antibody 327 (Oncogene Science). Immune complexes were washed three times with RIPA, and once with kinase buer (20 mM HEPES pH 7.0, 10 mM MnCl 2 ). One half of each immunoprecipitate was incubated in 50 ml kinase buer containing 5 mCi g-[ 32 P]ATP and 12.5 mg acid-denatured enolase at 378C for 5 min; the reaction was stopped by adding an equal volume of loading buer and the proteins resolved by 10% SDS ± PAGE followed by autoradiography. The other half of each immunoprecipitate was subjected to anti-c-Src immunoblotting.
Cell cycle analysis
Exponentially growing cells were trypsinized and collected in PBS. After 15 min of ®xation in 50% methanol, cells were incubated at 378C for 30 min. in the presence of 1 mg/ml ribonuclease A. DNA staining was performed at 08C by 30 min incubation with propidium iodide (50 mg/ml) in PBS containing 0.03% bovine serum albumin. Fluorescence was measured using a FACScan¯ow cytometer and data analysed using CellFIT Software (Becton-Dickinson).
Tumorigenicity and experimental metastasis
Six-week-old Balb/c athymic mice were purchased from Charles River (Calco, Italy). Care and use of the animals was in accordance with institutional guidelines. Mice (11 animals/cell type) were injected subcutaneously in the right ank with 5610 5 cells each, and tumors calibrated at regular intervals. Tumor volume was calculated as 0.56d1 2 6d2 (d1 and d2 being the larger and smaller diameter, respectively). For experimental metastasis, mice were injected in the tail vein with 1610 6 cells each (15 animals/cell type), examined daily, and sacri®ced when dyspnea was observed.
Abbreviations PTK, protein tyrosine kinase; PTP, protein tyrosine phosphatase; RTK, receptor tyrosine kinase; SFK, Src family kinase.
